Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

8.375 +0.175 (+2.13%)
Streaming Delayed Price Updated: 12:36 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Arvinas, Pfizer Plan To Broaden Development Of Breast Cancer Candidate ↗
Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) released clinical data for vepdegestrant (ARV-471) in combination with  
Via Benzinga
News headline image
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
From Arvinas Inc.
Via GlobeNewswire
News headline image
Analyst Ratings for Arvinas ↗
 
Via Benzinga
News headline image
Analyst Expectations for Arvinas's Future ↗
 
Via Benzinga
News headline image
Where Arvinas Stands With Analysts ↗
 
Via Benzinga
News headline image
7 Analysts Have This to Say About Arvinas ↗
 
Via Benzinga
News headline image
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
News headline image
Why Arvinas (ARVN) Shares Are Seeing Blue Skies ↗
Arvinas Inc (NASDAQ: ARVN) shares are trading higher by 11.2% to $24.32 Monday morning after the company announced an oversubscribed $350 million private placement. 
Via Benzinga
News headline image
Arvinas Announces Oversubscribed $350 Million Private Placement
From Arvinas Inc.
Via GlobeNewswire
News headline image
Barclays Maintains Overweight Rating for Arvinas: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
What 8 Analyst Ratings Have To Say About Arvinas ↗
 
Via Benzinga
News headline image
6 Analysts Have This to Say About Arvinas ↗
 
Via Benzinga
News headline image
Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ: AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter... 
Via Benzinga
Topics Stocks
News headline image
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
News headline image
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
Designation indicates entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP) 
From Arvinas Inc.
Via GlobeNewswire
News headline image
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
Collaboration expands Carrick’s clinical-stage Oncology program 
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Arvinas Announces Changes to its Board of Directors
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations ↗
Arvinas Inc (NASDAQ: ARVN) announced interim data from its Phase 1/2 dose escalation and expansion trial of ARV-766 in metastatic  
Via Benzinga
News headline image
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.